Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Inclusion Criteria: * histologically or cytologically confirmed unresectable advanced or metastatic nccRCC, including but not limited to: * Papillary RCC, any type * Unclassified RCC * Translocation RCC * Chromophobe RCC * Collecting duct RCC * Renal cell carcinoma with 80% or more sarcomatoid features on primary nephrectomy specimen or a biopsy * Other nccRCC histologies in discussion with principal investigator * Measurable disease as per RECIST 1.1. See Section 11 for the evaluation of measurable disease. * Age ≥ 18 years * ECOG performance status ≤1 (Karnofsky ≥70%, see Appendix A) * Participants must undergo fresh tumor biopsy after registration but prior to the start of treatment unless medically unsafe or not feasible. If a fresh tumor biopsy is not medically safe or not feasible, confirmation of the availability of archival tumor tissue is required. For archival tissue, a recommended minimum of 20 unstained slides should be obtained. * Normal organ and marrow function as defined below: * absolute neutrophil count ≥1,500/mcL * platelets ≥100,000/mcL * hemoglobin ≥9g/dL (transfusions allowed) * total bilirubin ≤2.0 x institutional upper limit of normal with the following exception: patients with known Gilbert disease should have a serum bilirubin ≤ 3 x ULN * AST(SGOT)/ALT(SGPT) ≤2.5 × institutional upper limit of normal with the following exception: patients with known liver metastases should have AST and ALT ≤ 5 x ULN * creatinine clearance ≥30…